Mobile

GvHD prophylaxis with ATG-Fresenius S in allogenic Stem Cell Transplantation from matched unrelated donors: A randomised phase III multicenter trial comparing a standard GvHD prophylaxies with cyclosp...

Mise à jour : Il y a 4 ans
Référence : EUCTR2004-000232-91

GvHD prophylaxis with ATG-Fresenius S in allogenic Stem Cell Transplantation from matched unrelated donors: A randomised phase III multicenter trial comparing a standard GvHD prophylaxies with cyclosporine A and Methotrexate with additional pretransplant ATG-Fresenius S

Femme et Homme

  • | Pays :
    • -
  • | Organes :
    • -
  • | Spécialités :
    • -

Extrait

Valutare l'efficacia di ATG-Fresenius S in aggiunta alla terapia standard (ciclosporina A/Metotressato) nel trattamento del fallimento precoce della terapia definito come il verificarsi della malattia del trapianto verso l'ospite di grado severo e acuta (grado III o IV) o di mortalita' precoce nei 100 giorni successivi al trapianto rispetto alla sola terapia standard.

Critère d'inclusion

  • GvHD prophylaxis with ATG-Fresenius S in allogenic Stem Cell Transplantation from matched unrelated donors

Liens